Brentuximab Vedotin,doxorubicin,vinblastine,dacarbazine,nivolumab
Seagen,BMS,takeda
['hodgkin', ' vedo', 'lymphoma', 'brentuximab', 'takeda', 'seagen']
brentuximab vedotin + immunotherapy shows 98% orr and 93% cr in patients with early-stage classical hodgkin lymphoma #adc #17icml #lymphoma #oncology #hematology
Onco’Zine reports about current research and development in hematology and oncology.